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PCLINICAL RESEARCH Acute Myocardial Infarction
Improvements in Long-Term Mortality
After Myocardial Infarction and Increased
Use of Cardiovascular Drugs After Discharge
A 10-Year Trend Analysis
Soko Setoguchi, MD, DRPH,* Robert J. Glynn, PHD, SCD,* Jerry Avorn, MD,*
Murray A. Mittleman, MD, DRPH,‡ Raisa Levin, MS,* Wolfgang C. Winkelmayer, MD, SCD*†
Boston, Massachusetts
Objectives We sought to assess the relationship between increasing use of cardiovascular medications and trends in long-
term prognosis after myocardial infarction (MI) in the elderly.
Background During the past decade, statins, beta-blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), and
angiotensin-II receptor blockers (ARBs) have been increasingly used after MI. However, little is known about the
relationship between increasing use of these medications and improvements in prognosis after MI.
Methods Using data from pharmacy assistance programs and Medicare in 2 states (1995 to 2004), we identified patients
with MI who survived 30 days after discharge. We assessed age, gender, race, comorbidities, and coronary
interventions during the MI hospitalization and recorded filled prescriptions for statins, BBs, ACEIs/ARBs, or anti-
platelet agents within 30 days after discharge. All patients were tracked until they died or until the end of the
eligibility/study period. We built multivariate Cox proportional hazards regression models to assess trends in
long-term mortality and the contribution to increasing medication use after MI.
Results Of 21,484 patients identified, 12,142 died during 74,982 person-years of follow-up. After adjusting for de-
mographics and comorbidities, we found that mortality after MI decreased significantly from 1995 to 2004
(hazard ratio for annual trend 0.97; 95% confidence interval 0.97 to 0.98), a 3% reduction in mortality each
year. Adjusting for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge completely
eliminated the association between time trend and mortality (hazard ratio 1.00; 95% confidence interval
0.99 to 1.01).
Conclusions The observed improvement in long-term mortality in elderly patients with MI may be mainly due to increased
use of cardiovascular medications after discharge. (J Am Coll Cardiol 2008;51:1247–54) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.063f
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eoronary artery disease is a major cause of morbidity and
he leading cause of death in the elderly. At least 410,000
en and 372,000 women age 65 years are annually
iagnosed with myocardial infarction (MI) in the U.S. (1).
owever, the incidence and mortality of coronary heart
isease have been decreasing during the past 3 decades,
resumably as the result of better control of coronary risk
rom the *Division of Pharmacoepidemiology and Pharmacoeconomics and †Renal
ivision, Department of Medicine, Brigham and Women’s Hospital and Harvard
edical School, and the ‡Division of Cardiovascular Medicine, Department of
edicine, Beth Israel Deaconess Medical Center and Harvard Medical School,
oston, Massachusetts. This work was funded by divisional funds and, in part, by a
cientist Development Grant from the American Heart Association to Dr. Winkel-
ayer (AHA 0535232N).W
Manuscript received July 23, 2007; revised manuscript received October 12, 2007,
ccepted October 17, 2007.actors and better clinical management, including revascu-
arization procedures and cardiovascular drugs (2–6). Stud-
es suggest that the outcomes of MI had been improving
rom the 1980s to the 1990s (7–10), but little is known
bout more contemporary trends in North America.
See page 1255
A wealth of evidence exists to support the efficacy of statins,
eta-blockers (BBs), angiotensin-converting enzyme inhibitors
ACEIs), angiotensin-II receptor blockers (ARBs), and anti-
latelet agents in patients with MI, and some studies have
hown that these medications are also cost effective (11–18)
uidelines for the management of patients after acute MI
mphasize use of these drugs for secondary prevention (19,20).
e have previously found that the use of these medications for
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Long-Term Mortality After MI and CV Drug Use April 1, 2008:1247–54secondary prevention after dis-
charge from MI has been increas-
ing during the past decade in el-
derly populations (21). It is
unknown, however, how that use
has impacted outcomes in popu-
lations of community-dwelling
elderly and to what extent the
increasing use of these medica-
tions has contributed to im-
provements in long-term mortal-
ity observed in older patients
after MI. In the current study,
we assessed whether the mortal-
ity of community-dwelling el-
erly after MI improved over time and the extent to which
he increasing use of preventive medications after discharge
ontributed to these changes in mortality.
ethods
ata sources and study population. We linked medical
laims data from several sources. Drug utilization data from
he New Jersey Pharmaceutical Assistance for the Aged and
isabled program (1994 to 2004) and the Pennsylvania
harmaceutical Assistance Contract for the Elderly pro-
ram (1994 to 2004) were merged with the complete
edicare claims for these beneficiaries. All traceable per-
onal identifiers were removed from the analytic dataset to
rotect patients’ privacy. These drug-assistance programs
rovide comprehensive prescription drug coverage for eligi-
le elderly patients in New Jersey and Pennsylvania. Patients
re eligible if their income is greater than the Medicaid annual
ncome threshold but less than approximately $35,000, thus
ncluding primarily lower middle-class elderly. Neither of these
rograms had any restrictions or prior authorization programs
n place for any of the study drugs.
We identified all patients who were admitted to a hospital
or MI between January 1, 1995, and December 31, 2004.
o ensure enrollment status, all patients were required to
ave at least 1 claim for any service and at least 1 filled
rescription during the 365 days before the index MI
ospitalization. An MI admission was defined as a
ospitalization of at least 3 days and not more than 180
ays with an International Classification of Diseases,
ersion 9, diagnosis code of 410 in the primary or
econdary position at discharge. This algorithm to iden-
ify MI hospitalizations has been validated and been
hown to have a positive predictive value of 94% (22). We
urther required all study patients to survive and remain
ligible for pharmacy benefits for at least 30 days from the
ischarge date of the index MI hospitalization. We excluded
atients who were admitted to a nursing home in the year
receding the MI or the 30 days after discharge. Survival
ime for each patient was considered from the index date
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin-II
receptor blocker
BB  beta-blocker
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary interventionthe 31st day after discharge from the index MI) to the date tf death, the date of lost eligibility, or the end of the
ollow-up period (August 31, 2005).
ovariates. We obtained information on each patient’s age
n the index MI admission, gender, and race (white vs.
onwhite [including black, Hispanic, Asian, and Native
merican]) from enrollment files. We used recorded diag-
oses in inpatient and outpatient claims to assess the
resence of comorbid conditions including other indications
nd contraindications for statin, BB, and ACEI/ARB
uring the 12-month period preceding the discharge date.
he comorbid conditions included hypertension, coronary
rtery disease, previous MI (22), heart failure (23), cerebro-
ascular disease (24), peripheral artery disease (24), atrial
brillation, arthritis (25), diabetes, chronic kidney disease
26), maintenance dialysis, chronic pulmonary disease, al-
ohol abuse, dementia, depression, other mental disease, any
alignancy, obesity, and the Charlson comorbidity index.
e also defined the characteristics of the index MI includ-
ng length of stay for the index MI admission and admin-
stration of coronary interventions such as percutaneous
oronary interventions (PCIs) (i.e., percutaneous translumi-
al coronary angioplasty or coronary stent placement),
evascularization surgery, or infusion of thrombolytic
gents. We created indicators for previous health care
tilization (number of days for admissions, physician visits,
nd prescriptions for different medications filled). Finally,
e assessed whether the patients had at least 1 filled
rescription for any statin, BB, ACEI/ARB, and nonaspirin
ntiplatelet agent (clopidogrel or ticlopidine) within 30 days
fter discharge from the index MI hospitalization.
tatistical analysis. We constructed Kaplan-Meier cumu-
ative mortality curves starting at the 31st day after discharge
o describe unadjusted mortality among the patients dis-
harged after MI (not shown). Adjusted time trends as well
s the effect of each calendar year on mortality were analyzed
n multivariate Cox proportional hazards regression models,
ncluding age, gender, race, comorbidities, and health ser-
ice utilization measures (27). We accounted for clustering
f patients within hospitals by using the robust sandwich
stimator of Wei et al. (28). The sandwich estimator is a
eneral method for estimating the covariance matrix of
arameter estimates, which provides consistent estimates
ven when a model is not correctly specified. The propor-
ionality assumption was tested by including interaction
erms between calendar year and study time. To assess
hether the change in cardiovascular drug use and/or
hrombolytic therapies/revascularization procedures medi-
ted the effect of calendar year on mortality, we sequentially
ntroduced indicator terms for these therapeutic interven-
ions into the multivariate Cox models described above (29).
azard ratios are presented together with the corresponding
5% confidence intervals. We used SAS for Windows
oftware (release 9.2) for all statistical analyses (SAS Insti-
ute, Cary, North Carolina).
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tudy patients and characteristics. We identified 28,754
atients admitted for MI between January 1, 1995, and
ecember 31, 2004, who had been active participants in
heir insurance programs for 1 year before the index MI
dmission and for 30 days after the index MI discharge.
f these, 21,484 (74.7%) survived at least 30 days after
ischarge, constituting the final study cohort. Characteris-
ics of these patients overall and by calendar year are shown
n Table 1. In the entire study population, the mean age was
0 years, and 73% were women. Several comorbid condi-
ions were highly prevalent: 62% of all patients had previ-
usly been diagnosed with coronary artery disease, 66% had
eart failure, 32% had cerebrovascular disease, 46% had
iabetes, 39% had chronic pulmonary disease, and 17% were
iagnosed with chronic kidney disease. When stratified by
alendar year, we observed increases in age and the preva-
ence of diagnosis for hypertension, peripheral vascular
iseases, cerebrovascular diseases, diabetes, chronic kidney
isease, dementia, and depression over the study period.
he use of PCI (percutaneous transluminal coronary angio-
lasty or stent) also increased over time (all p values0.05),
hereas the use of thrombolytic therapy as well as the length
f stay for the index MI admission decreased. Use of statins,
Bs, ACEIs/ARBs, and antiplatelet agents after the index
I admission also increased over time (all p values 0.01).
ortality. Among the 21,484 study patients, there were
2,142 deaths during 74,982 person-years of follow-up. The
-, 3-, and 5-year mortalities were 20%, 41%, and 57%,
espectively.
ultivariate analysis. We estimated unadjusted and ad-
usted effects of calendar year by using Cox proportional
azards regression models (Table 2). In unadjusted analyses,
e did not observe a temporal trend in mortality after MI.
owever, after simultaneously adjusting for changes in
atient demographics, comorbidities, and health service use
easures over time, we found that mortality after MI
mproved by 3% per year from 1995 to 2004 (Table 2). The
ully-adjusted effect of calendar year was also estimated
sing indicator variables for each interval of the calendar
ear, which was consistent with the decreasing trend of
ortality after MI observed in the previous model (Table 2,
ig. 1). We found no violation of the proportionality
ssumption (p  0.7).
To assess whether the secular trends toward greater use of
nvasive cardiac procedures and/or the study medications
xplained the improvement in mortality after MI over time,
e sequentially added these factors to the fully adjusted Cox
roportional hazards regression model (Table 3). After
dding the indicator terms for the use of the study medi-
ations (statins, BBs, ACEIs/ARBs, and antiplatelet
gents) to the previously described fully adjusted Cox
odel, the temporal trend of improving mortality after MI
isappeared (Table 3). However, when the indicator for
CIs was added to the fully adjusted model without dncluding terms for the use of cardiovascular medications
fter MI, the associations of calendar year with mortality
ere attenuated but remained statistically significant. When
e then added indicator terms for both PCIs and medica-
ion use, we found the effect of calendar year was very
imilar to those in the model with the term for medication
se only without the term for PCI (Table 3), which suggests
hat the improving trend in mortality may be primarily
ttributable to increased use of recommended drugs,
hereas the effect of PCI was much less pronounced than
hat attributable to medication use. These observations were
isplayed in Figure 1, by comparing the hazard ratios and
5% confidence intervals for each calendar year before and
fter adjusting for the use of coronary interventions or the
se of the recommended cardiovascular drugs after dis-
harge from MI.
iscussion
n this large sample of 21,484 community-dwelling elderly,
e studied temporal trends in mortality after hospitalization
or MI. After adjusting for patients’ demographics, comor-
idities, duration of the MI hospitalization, patterns of
revious health services use, and clustering of patients
ithin hospitals, post-MI mortality improved over time by
pproximately 3% per year. Further analyses revealed that
his trend toward better prognosis after discharge from MI
isappeared completely after adjustment for use of statins,
Bs, ACEIs/ARBs, and antiplatelet agents, all generally
ecommended for use after MI. This relationship was not
erely an ecological observation; it emerged by analysis of
he medication use and mortality experience of each indi-
idual subject. Thus, our study suggests that the observed
mprovements in mortality over time may predominantly be
ttributable to and mediated through the increasing use of
tatins, BBs, ACEIs/ARBs, and antiplatelet agents over the
ecade of observation.
We also found that the association between calendar year
nd mortality was attenuated after adjusting for the use of
oronary intervention during the index hospitalization, but
as less pronounced than the reduction attributable to drug
se. The findings suggest that coronary intervention may
lso have contributed to improved mortality, but to a lesser
egree. Because use of coronary intervention was highly
ssociated with use of recommended cardiovascular drugs
21), the attenuation of the calendar effect after adjustment
or coronary intervention could also be explained by the
pparent correlation between the use of procedures and
rugs. Patients who underwent coronary interventions had
mproved long-term mortality, but the observed improve-
ent of long-term mortality in the entire study patients was
ot fully explained by the change in the use of PCI.
n-hospital mortality as well as 30-day mortality after MI
dmission also improved over time in a separate analysis
not shown). After adjusting for coronary intervention
uring the MI hospitalization, these temporal trends toward
Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year
Table 1 Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
p Value
for Trend All Years
% nursing home patients prior to admission 6.1 7.4 9.1 10.3 12.1 13.2 13.7 14.3 13.9 16.3
% nursing home patients within 30 days after discharge 11.4 13.7 17.6 22.5 22.4 26.0 27.9 27.6 30.2 29.5
Total population (n) 2,697 3,123 2,518 2,278 2,158 1,953 1,773 1,809 1,715 1,460 — 21,484
Follow-up (yrs) 4.6 (3.6) 4.6 (3.3) 4.4 (3.0) 4.1 (2.6) 3.7 (2.3) 3.3 (1.9) 2.9 (1.5) 2.3 (1.1) 1.7 (0.7) 1.0 (0.4) .0001 3.5 (2.7)
Age (yrs) 78.7 (6.7) 79.2 (6.8) 79.3 (6.9) 79.9 (6.8) 79.8 (6.7) 80.5 (6.7) 80.2 (7.0) 80.2 (7.2) 80.3 (7.2) 80.5 (7.2) .0001 79.9 (6.9)
Male 28.0 28.4 27.2 27.5 27.1 25.6 26.3 27.6 27.9 28.0 0.4770 27.4
Race (black) 5.6 5.5 5.4 5.4 6.0 7.3 7.1 6.0 5.5 7.1 0.0122 6.0
Health service use
Previous hospitalization 40.5 34.5 34.6 34.9 35.0 34.6 34.0 35.7 34.3 33.8 0.0010 35.4
No. of physician visits 10.1 (6.6) 9.6 (6.9) 9.7 (6.9) 10.2 (7.0) 9.9 (7.2) 10.2 (7.8) 9.8 (6.9) 10.5 (7.8) 10.5 (7.9) 10.5 (8.5) .0001 10.1 (7.3)
No. of medications 9.4 (5.5) 9.3 (5.4) 9.9 (5.8) 10.0 (5.6) 10.4 (5.9) 10.7 (6.1) 11.1 (6.3) 11.1 (6.0) 11.2 (5.9) 11.6 (6.2) .0001 10.3 (5.9)
Charlson comorbidity scores 2.6 (2.2) 2.4 (2.0) 2.5 (2.1) 2.6 (2.1) 2.7 (2.1) 2.7 (2.2) 2.7 (2.1) 2.9 (2.2) 2.8 (2.1) 2.7 (2.1) .0001
Procedures during index MI admission
Angiography including PCI 34.6 39.1 40.5 43.1 43.8 44.4 49.6 52.1 53.4 53.0 .0001 44.1
Angiography only 21.3 23.2 24.8 23.2 24.0 23.6 24.4 25.8 24.6 22.5 0.0332 23.6
PTCA 13.2 15.8 15.6 19.6 19.5 20.5 24.7 25.8 28.3 30.3 .0001 20.2
Stent 1.9 6.2 9.6 15.5 17.1 18.8 22.8 24.3 26.8 29.0 .0001 15.4
Revascularization surgery 7.2 8.4 8.8 7.8 7.9 7.6 7.1 7.8 7.1 6.4 0.0468 7.7
Thrombolytic therapy 2.0 2.2 1.9 1.6 1.5 1.6 1.2 1.0 1.1 1.2 .0001 1.6
Length of stay for the index MI 11.1 (7.4) 10.8 (7.4) 10.6 (7.9) 9.7 (6.2) 9.6 (6.6) 9.6 (7.2) 9.3 (7.1) 9.2 (6.6) 9.2 (6.8) 9.0 (7.2) .0001 10.0 (7.1)
Previous diagnosis
Coronary artery disease 65.7 63.0 61.7 62.6 64.5 62.5 59.8 61.5 60.5 57.1 .0001 62.2
Prior MI 9.4 6.4 5.9 5.6 6.8 7.4 7.8 6.3 8.1 9.4 0.1990 7.2
Atrial fibrillation 29.6 30.4 32.0 31.9 33.3 33.8 34.6 34.1 35.3 33.4 .0001 32.5
Aortic aneurysms 3.7 4.1 3.1 3.8 3.4 5.3 3.8 4.4 5.5 5.1 0.0003 4.1
Peripheral vascular diseases 23.7 22.6 25.1 25.6 26.2 27.3 27.9 27.1 28.6 27.4 .0001 25.8
Hypertension 66.4 68.2 70.1 71.7 72.3 74.9 78.6 80.2 83.8 82.1 .0001 73.6
Cerebrovascular disease 29.4 29.0 29.2 29.5 31.8 34.0 35.0 33.9 35.2 34.7 .0001 31.7
Heart failure 65.3 64.5 65.4 66.3 66.6 66.4 64.6 66.7 66.2 63.4 0.8278 65.5
Diabetes 46.2 42.9 45.1 45.3 46.6 45.1 47.1 47.9 50.1 49.3 .0001 46.2
Chronic pulmonary diseases 36.7 36.0 37.5 39.2 41.9 39.0 38.9 43.0 41.9 41.0 .0001 39.1
Chronic kidney diseases 14.5 13.5 15.3 15.9 16.0 18.1 17.5 19.6 22.6 22.9 .0001 17.0
Dialysis 1.8 1.4 2.0 2.0 1.9 2.7 2.5 2.4 2.2 2.1 0.0066 2.0
Rheumatoid arthritis 3.2 3.4 3.8 5.1 4.6 3.8 4.1 4.4 4.4 3.6 0.0723 4.0
Osteoarthritis 34.0 33.4 35.2 36.3 36.1 39.3 39.6 39.2 40.8 38.2 .0001 36.7
Cancer (except for nonmelanoma skin cancer) 20.2 19.1 19.5 19.5 19.6 20.7 21.6 23.3 21.5 19.5 0.0141 20.3
Dementia 7.5 7.5 7.3 7.8 9.4 10.3 11.4 10.9 12.5 12.9 .0001 9.3
Depression 12.5 12.2 12.7 14.1 15.1 17.1 17.4 16.5 19.3 20.4 .0001 15.2
Continued on next page
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April 1, 2008:1247–54 Long-Term Mortality After MI and CV Drug Usemproved mortality were no longer present, suggesting that
mprovement in short-term mortality may be due to in-
reased use of PCIs. These findings suggest that increased
se of PCI may have predominantly improved acute and
hort-term mortality, whereas increased use of preventive
edications may be responsible for improvements in
onger-term outcomes in the population we studied.
Unadjusted analyses indicated that there was no change
ver time in temporal trends in mortality after MI. It was
nly after simultaneous control for differences in age,
ender, race, and comorbidities that significant improve-
ents in long-term mortality were observed. This is com-
atible with our findings of increases over time in age and
ajor comorbidities in our population of MI patients (Table
). A possible explanation of this may lie in the trends
oward inclusion in the sample of older patients with more
omorbidities in more recent years. Indeed, advances in
cute and subacute treatment of MI during the past decade
ay have enabled older and sicker patients to survive their
cute event, be discharged alive, and thus be selected into
ur study cohort.
The existing literature on trends in mortality after MI
ospitalization in North America is rather limited, and most
f its observations are now outdated. Using data for MI
atients discharged from greater Worcester hospitals, Fur-
an et al. (30) observed that multivariate adjusted 2-year
ortality after discharge from hospitals declined over time
or both Q-wave and non–Q-wave MI between 1975 and
997. Using more recent data from the same data source
nd adjusting for demographics, cardiovascular comorbidity,
nd MI characteristics, Botkin et al. (31) found a modest
mprovement in the 1-year post-discharge mortality over
he period between 1975 and 2001. Pashos et al. (7)
eported from Medicare data that 30-day (26% to 23%) and
-year (40% to 36%) mortality of elderly patients with MI
mproved throughout the U.S. from 1987 to 1990 (7). They
lso found that the proportion of patients undergoing
evascularization procedures (both surgery and PCI) in-
reased from 13% to 21% and concluded that this may
xplain the observed improvement in the mortality. Tu et al.
9) reported a similar observation in Ontario between 1992
nd 1996. They found that both the overall 30-day risk-
djusted mortality and the 1-year risk-adjusted mortality
eclined modestly (16% to 14% for 30-day and 24% to 22%
or 1-year mortality) along with a significant increase in the
se of coronary intervention including surgery and PCI.
ilote et al. (10) demonstrated a mortality decrease in MI
atients in Quebec between 1988 and 1995, which was
aralleled by an increase in the use of cardiac procedures,
spirin, BBs, ACEIs, and lipid-lowering agents. Most
ecently, Ford et al. (32) attempted to explain the
ecrease in U.S. overall deaths from coronary disease
etween 1980 and 2000 using a previously validated
odeling approach. They found that approximately 47%
f the decrease in coronary deaths over that period was
attributable to treatments, including revascularizationT U Va
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ling approach used in their article relied on data from
any different sources and assumptions in estimating
ffectiveness of the medications and procedures. On the
ther hand, we used real-world observations from a
ell-defined population that allowed us to directly esti-
ate effectiveness of the treatment and link individual
rognosis and use of drugs and procedures.
Our study covers more contemporary years with a decade
f observations and showed that the mortality trend after
I has further improved. Beyond previous studies, we
ssessed the contribution of the use of recommended
edications after discharge for MI in the outpatient setting
ather than during the MI hospitalization. Because provid-
rs of care after discharge are often different from physicians
aring for patients during hospitalization, drug use after
ischarge may be a better marker of long-term use of these
rugs. To our knowledge, this is the first study to suggest
hat improvements in prognosis after MI may be attrib-
table to increased use of medication for secondary
revention using actual observations from the real-world
opulation.
tudy limitations. The following limitations should be
oted. First, we used the International Classification of
iseases, version 9, code of 410 to identify patients who
ere hospitalized for MI. Although this definition was
hown to have very high accuracy, the use of this code has
radually evolved to include patients diagnosed for MI
ased on troponin values using increasingly sensitive assays,
specially after publication of the American Heart Associ-
tion/American College of Cardiology guidelines with a
evised definition of MI in 2000 (33). As a result, patients
ssociations Between Calendar Year and Mortality After the Index
Table 2 Associations Between Calendar Year and Mortality Aft
Variables Adjusted for
a. None (unadjusted)
b. Age
c. Demographics (age, gender, and race)
d. Demographics and comorbidities*
e. Demographics, comorbidity, length of stay, Charlson score, and health
service use†
f. Previous model, but dummy coded for year instead of a trend indicator
Comorbidities include previous MI, non-MI coronary artery diseases, heart failure, cerebrovascular d
ulmonary diseases, peptic ulcer diseases, liver diseases, chronic kidney diseases, dialysis, maligna
ther mental disorders, obesity, and alcohol abuse. †Health service use measures include numbe
Abbreviations as in Table 1.iagnosed in recent years may include MI patients who had0.4
0.6
0.8
1.0
1.2
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Calendar Year
†H
az
ar
d 
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r 
C
al
en
da
r 
Y
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r
Not Adjusted for CV drug use/coronary interventions
Adjusted for CV drug use
Adjusted for use of coronary interventions
Figure 1 Hazard Ratio for Calendar Year Before and After
Adjusting for CV Drug or Coronary Intervention
After adjusting for changes in demographics and comorbidities over time (red
squares), we found that long-term mortality after myocardial infarction (MI)
decreased significantly from 1995 to 2004, with a 3% reduction in the risk of
death each year. Next, we adjusted for the use of statins, beta-blockers, angioten-
sion-converting enzyme inhibitors/angiotensin-II receptor blockers, and nonaspirin
antiplatelet drugs after discharge, which eliminated the association between time
trend and mortality (blue circles). This means that the change in mortality may be
primarily attributable to increased use of recommended drugs. In contrast, adjust-
ing for the use of coronary interventions, but not for the study drugs (green trian-
gles), diminished the time trend slightly but did not eliminate the effect completely
†Hazard ratios for calendar years were estimated from the multivariate Cox propor-
tional hazards regression model that includes indicators for each calendar year,
age, gender, race, comorbidities (previous MI, non-MI coronary artery diseases,
heart failure, cerebrovascular diseases, peripheral vascular diseases, atrial fibrilla-
tion, aortic aneurysms, diabetes, hypertension, chronic pulmonary diseases, peptic
ulcer diseases, liver diseases, chronic kidney diseases, dialysis, malignancy, rheu-
matoid arthritis, osteoarthritis, human immunodeficiency virus infection, dementia,
depression, other mental disorders, obesity, and alcohol abuse) and health service
use measures (number of visits, number of generic medications prescribed, and
any hospitalization). The p value for the trend was estimated from the same model
replacing the indicators for each calendar year by 1 continuous variable for calen-
dar year. CV  cardiovascular.Date in 21,484 Survivors of MI
er the Index Date in 21,484 Survivors of MI
Calendar Year Hazard Ratio
95% Confidence
Interval p Value
Trend 1.00 0.98–1.01 0.7805
Trend 0.99 0.97–1.00 0.0464
Trend 0.99 0.97–1.00 0.0584
Trend 0.98 0.97–0.99 .0001
Trend 0.97 0.96–0.98 .0001
1995 1.00 (Reference) —
1996 0.92 0.85–0.99 0.0221
1997 0.87 0.82–0.93 .0001
1998 0.89 0.82–0.95 0.0008
1999 0.88 0.83–0.94 .0001
2000 0.84 0.78–0.90 .0001
2001 0.82 0.76–0.88 .0001
2002 0.81 0.75–0.88 .0001
2003 0.79 0.72–0.87 .0001
2004 0.76 0.67–0.86 .0001
iseases, peripheral vascular diseases, atrial fibrillation, aortic aneurysms, diabetes, hypertension, chronic
ncy, rheumatoid arthritis, osteoarthritis, human immunodeficiency virus infection, dementia, depression,
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ncluding non–ST-segment elevation MI (NSTEMI).
owever, although short-term prognosis (in-hospital or
0-day mortality) has been shown to be better in NSTEMI,
ong-term mortality has been shown to be similar or worse
ith NSTEMI (30,34,35). Because we assessed long-term
ather than short-term prognosis, the observed mortality
rend is unlikely to be explained by the change in the
iagnostic method, coding, or relative contribution of
TEMI versus NSTEMI. Furthermore, if the change in
nclusion of STEMI versus NSTEMI is the reason for
mproving mortality over time, the trend in mortality would
ot be mediated by cardiovascular drug use, but rather
hould remain significant after the inclusion of these terms.
onetheless, our results could be explained in part by the
hange in the method of diagnosing MI.
Another limitation is that our data did not contain any
nformation on other recommended strategies for secondary
revention; aspirin is available over the counter, which leads
o underascertainment of its use from claims data. However,
tudies have showed that rates of aspirin use after MI have
emained relatively constant over the past decade (36,37).
nformation on counseling for and successful implementa-
ion of smoking cessation, weight control, diet modification,
xercise, and other life-style modifications also was not
vailable in our study. We cannot rule out that increased use
f the study drugs is associated with more health-conscious
ehaviors, thus contributing to the beneficial effect that we
ight attribute to medication use alone. However, life-style
nterventions have been recommended for the secondary
revention of MI for several decades; thus, these behaviors
re unlikely to have increased to a similar extent compared
ith the use of the study drugs or coronary interventions.
Many factors are associated with prognosis after MI,
ssociations between Calendar Year and Mortality in 21,484 Survitilization of Coronary Int rventions* and of Recommended Cardio
Table 3 Associations between Calendar Year and Mortality in 2Utilization of Coronary Interventions* and of Recomme
Variables Adjusted for
Model e. in Table 2  statin, ACE/ARB, BB, and antiplatelet after discharge from MI
Model e. in Table 2  PCI during MI admission but without cardiovascular drug use
Model e. in Table 2  statin ACE/ARB, BB, and antiplatelet after discharge from MI,
and PCI, revascularization surgery, and use of thrombolytic agents during MI
admission
Previous model, but dummy coded for year instead of a trend indicator
Coronary interventions include PCIs, revascularization surgery, or infusion of thrombolytic agents
Abbreviations as in Table 1.nd some were not measured in the present study, but
shese would need to meet certain conditions to allow an
lternative explanation for our findings. These unmea-
ured factors would have to be associated with the
alendar year and with cardiovascular medication use
fter discharge. Although our study has a number of
imitations, these factors cannot be easily measured in the
arge population-based samples represented in this study.
ur study generated a hypothesis that increasing drug use
ay explain improved long-term mortality of MI patients
n the past decade. Further investigation will be necessary
o elucidate the relative and individual contributions of
hese unmeasured factors.
onclusions
his large study of community-dwelling elderly with MI
ndicates that long-term mortality from MI after discharge
as improved significantly during the last decade and that
he observed decrease in mortality may be attributable in
arge part to improved practice related to use of cardiovas-
ular medications after MI. To a lesser degree, it may be
ttributable to increased use of PCIs during MI hospital-
zations. Our results suggest that the efficacy of these
edications after MI for secondary prevention has been
ffectively translated into nontrial elderly populations.
hese data should encourage clinicians to continue use of
hese proven therapies in the management of elderly pa-
ients after MI.
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